BMS’ RayzeBio bags rights for Philochem’s radiopharma asset for $350M upfront
Bristol Myers Squibb’s subsidiary RayzeBio is spending $350 million upfront to license an early-stage radiopharmaceutical candidate for prostate cancer from Philochem. RayzeBio will get global rights to a preclinical actinium-based asset, called OncoACP3, which is ...
Bristol Myers Squibb’s subsidiary RayzeBio is spending $350 million upfront to license an early-stage radiopharmaceutical candidate for prostate cancer from Philochem.
RayzeBio will get global rights to a preclinical actinium-based asset, called OncoACP3, which is ...
